SELLAS Life Sciences Group, a clinical stage biopharmaceutical company based in New York, develops immunotherapeutics for cancer, including galinpepimut-S and SLS009. The company went public in 2008 and employs 16 staff.
Noah D Beerman bought 10,000 shares of SLS on 9 July at $2.23 per share, worth a total of $22K. They now own 15,407 SLS shares, or a 185% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.